Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
106.45
+3.52 (3.42%)
May 8, 2026, 9:49 AM EDT - Market open
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
| 400.59M | 360.01M | 213.30M | | | |
| 11.27% | 68.78% | 50.42% | | | |
Bile Acid Medicines Revenue | 169.02M | 161.31M | 123.11M | | | |
Bile Acid Medicines Revenue Growth | 4.78% | 31.02% | 232.03% | | | |
Total Product Revenue, Net | 569.61M | 521.31M | 336.41M | | | |
Total Product Revenue, Net Growth | 9.26% | 54.96% | 88.07% | | | |
License and Other Revenue | - | - | 479.00K | | | |
License and Other Revenue Growth | - | - | -93.61% | | | |
| 569.61M | 521.31M | 336.89M | | | |
| 9.26% | 54.74% | 80.76% | | | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
License and Other Revenue | - | - | 479.00K | | | |
License and Other Revenue Growth | - | - | -93.61% | | | |
United States - Product Revenue | 442.55M | 401.55M | 274.17M | | | |
United States - Product Revenue Growth | 10.21% | 46.46% | 86.89% | | | |
Rest of the World - Product Revenue | 127.06M | 119.77M | 62.24M | | | |
Rest of the World - Product Revenue Growth | 6.09% | 92.44% | 93.43% | | | |
| 569.61M | 521.31M | 336.89M | | | |
| 9.26% | 54.74% | 80.76% | | | |
Updated May 6, 2026. Data Source:
Fiscal.ai.
